Clinical utility of C‐terminal telopeptide of type 1 collagen in multiple myeloma

Summary Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. We measured C‐terminal telopeptide of type I collagen (CTX‐1), and Procollagen type 1 N Propeptide (P1NP) in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2016-04, Vol.173 (1), p.82-88
Hauptverfasser:	Ting, Kay R., Brady, Jennifer J., Hameed, Abdul, Le, Giao, Meiller, Justine, Verburgh, Estelle, Bayers, Christopher, Benjamin, Dalia, Anderson, Kenneth C., Richardson, Paul G., Dowling, Paul, Clynes, Martin, Fitzgibbon, Maria C., O'Gorman, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Bone Diseases - blood Bone Diseases - drug therapy bone markers bone resorption Collagen Type I - blood CTX‐1 Female Humans Male Middle Aged multiple myeloma Multiple Myeloma - blood Multiple Myeloma - drug therapy myeloma bone disease Neoplasm Proteins - blood Peptide Fragments - blood Procollagen - blood
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Myeloma bone disease (MBD) is a major cause of morbidity in multiple myeloma (MM). We investigated bone turnover markers (BTM) as relapse predictors and biomarkers for monitoring MBD. We measured C‐terminal telopeptide of type I collagen (CTX‐1), and Procollagen type 1 N Propeptide (P1NP) in 86 MM patients and 26 controls. CTX‐1 was higher in newly diagnosed patients compared to control, remission and relapse (P
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.13928